CJC-1295 in sports medicine: the evidence

A scoping review published on 11 August 2026 in the American Journal of Sports Medicine examined six peptides athletes and gym-goers are currently sourcing outside regulated channels^[1]. One of those six is CJC-1295, a long-acting analogue of growth-hormone-releasing hormone. The review authors, from the Department of Orthopaedic Surgery at UCLA, reached a clear verdict: the claimed benefits of CJC-1295 and the other five peptides for musculoskeletal recovery and athletic performance remain unsubstantiated by current human trials.

What CJC-1295 is and how it works

CJC-1295 binds the growth-hormone-releasing hormone (GHRH) receptor on the anterior pituitary and stimulates the release of growth hormone. The version with a drug affinity complex (DAC) attaches covalently to circulating albumin, which extends its half-life to 5.8 to 8.1 days from the minutes-long window of native GHRH. A single subcutaneous dose in healthy adults raised mean plasma growth-hormone concentrations two to ten times above baseline for six days or more, with IGF-1 elevated 1.5 to three times baseline for nine to eleven days^[2]. The version without DAC, often sold under the same CJC-1295 label, is structurally identical to MOD-GRF(1-29) and has a half-life of roughly thirty minutes, making the two molecules pharmacologically distinct despite their common name. See the CJC-1295 peptide page for a full breakdown of the chemistry.

What the 2026 sports medicine literature found

The UCLA scoping review (Tewari et al., 2026) found that 67 percent of publications on the six reviewed peptides used preclinical animal models^[1]. For CJC-1295 paired with ipamorelin, animal work showed improved muscle tension (maximum tetanic tension in murine models), but no controlled human trial for any orthopaedic or sports medicine indication has been completed. A companion primer for orthopaedic and sports medicine physicians published earlier in 2026 by Mayfield et al. stated plainly that for CJC-1295 and ipamorelin together, "information regarding the indications, dosing, frequency, and duration of treatment remains unknown"^[3].

A structured narrative review published in JBJS Reviews, covering studies from January 2020 through August 2025, placed growth hormone secretagogues including CJC-1295 in the same category as other regenerative peptides: compounds that "remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions"^[4]. A review in Sports Medicine by Mendias and Awan (2026) reinforced the point, noting that rigorous human safety data are scarce and that the grey market introduces an additional layer of risk from products of unknown purity and identity^[1].

The human evidence available for CJC-1295

The published human dataset for CJC-1295 consists primarily of two small pharmacokinetic studies conducted in 2006, both sponsored by ConjuChem, the company that developed the DAC chemistry platform^[2]. Teichman et al. dosed healthy adults aged 21 to 61 at 30 to 60 micrograms per kilogram subcutaneously and observed no serious adverse events in the short observation window. Ionescu and Frohman (2006) confirmed that pulsatile growth-hormone output was preserved rather than flattened under sustained GHRH-receptor stimulation, a mechanistic finding that distinguished CJC-1295 from continuous GHRH infusion.

ConjuChem's Phase 2 programme did not proceed to completion. No other sponsor has advanced CJC-1295 into a Phase 2 or Phase 3 efficacy trial for any indication. The sports medicine claim, that CJC-1295 improves muscle recovery, tendon healing, or athletic performance in humans, has no controlled trial evidence behind it. The animal work is real, but animal findings do not confirm human effect sizes, appropriate doses, or long-term safety.

Regulatory status and antidoping risk

CJC-1295 has no marketing authorisation from the FDA, the EMA, the MHRA, or any national agency covered on this site. The only DailyMed listing is a bulk ingredient entry for veterinary compounding. The World Anti-Doping Agency prohibits CJC-1295 under section S2 of the Prohibited List (peptide hormones, growth factors, related substances, and mimetics) as a GHRH-releasing-factor analogue. The ban applies both in and out of competition. Any competitive athlete who tests positive for CJC-1295 faces a doping violation regardless of therapeutic intent. Per-country regulatory detail is on the CJC-1295 regulation pages.

A practical complication for users who purchase from the grey market is that the with-DAC and without-DAC versions are routinely sold under the same label. A Certificate of Analysis that explicitly identifies which molecule is in the vial, and confirms the molecular formula by mass spectrometry, is the only way to know what has been purchased. The dosing logic differs between the two variants because their half-lives differ by a factor of roughly 300, and a vendor-supplied label reading only 'CJC-1295' does not resolve the question.

What the 2026 review says for clinical practice

The Tewari et al. scoping review recommended that physicians advise patients to avoid using these peptides as alternatives to established orthopaedic treatments until adequately powered human studies are available^[1]. The Mayfield et al. primer echoed this, calling for significant additional research before definitive recommendations can be made to patients. Neither review suggested that the existing animal evidence justifies current clinical use.

For a reader considering CJC-1295 for a musculoskeletal indication, the honest position from the 2026 peer-reviewed literature is that animal models show pharmacological activity, the two 2006 human studies describe the pharmacokinetics of a single dose in healthy volunteers, and no human trial has tested the compound for the recovery or performance claims that drive grey-market demand. The CJC-1295 peptide page documents all known sources and the regulatory picture in full.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Consult a qualified healthcare professional before using any peptide product.